Health

COVID-19: Serum Institute CEO Adar Poonawalla reveals cost of Covishield vaccine – Check price here

The Drug Controller General of India (DCGI) Dr VG Somani on Sunday (January 3) approved Serum Institute of India’s Covishield and Bharat Biotech’s Covaxin for emergency use against coronavirus.  DGCI approved the roll-out of these vaccines in India.

Meanwhile, the Serum Institute of India CEO Adar Poonawalla on Sunday revealed the costs of Covishield and disclosed that his company has fixed two different prices for the vaccine.

Poonawalla announced that Covishield are going to be given at Rs 250 to the govt and therefore the vaccine are going to be available within the private marketplace for Rs 1,000. consistent with Poonawalla, Serum’s Covishield is cheaper than the vaccine developed by Pfizer-BioNTech and its transportation is additionally easy as compared to Pfizer’s vaccine. Poonwalla also said that his company, which is predicated in Pune, is making 50-60 million doses of the Oxford-AstraZeneca vaccine monthly .

The SII CEO said that the Indian government wants to vaccinate quite 130 crore people within the country by mid-2021. “We are able to provide the vaccine for the govt . we’ve sent our proposal and are expecting the contract to be signed with the govt . The vaccine are going to be made available to the govt within 10 days of the contract,” he said.

According to Poonawalla, Serum Institute is yet to receive permission from the govt to export the vaccine. “We have bilateral relations with Saudi Arabia and a few other countries. we’ve sought permission from the govt during this regard. After getting this approval, we’ll be ready to deliver our medication to quite 50 countries of the planet ,” he said.

The DGCI granted the approval to Covishield and Covaxin after a topic Expert Committee of Central Drugs Standard Control Organisation (CDSCO) recommended these two vaccines for emergency use in India. it’s going to be recalled that Covishield was recommended for emergency use on January 1, whereas Covaxin was recommended for restricted use on January 2.

Prime Minister Narendra Modi has welcomed the DCGI decision and said that approval of two vaccines may be a decisive turning point to strengthen a spirited fight.

“DCGI granting approval to vaccines of Serum Institute and Bharat Biotech accelerates the road to a healthier and COVID-free nation. Congratulations India. Congratulations to our hardworking scientists and innovators,” he said.

Show More

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button